Bringing a new drug to market is an enormously complex and expensive process, often taking over a decade and costing upwards of $2 billion. The pharmaceutical industry faces increasing pressure to improve R&D productivity and efficiency. Artificial intelligence (AI) has recently emerged as a transformative technology to accelerate and enhance many aspects of drug discovery. From virtual screening of compound libraries to predicting clinical trial outcomes, machine learning and other AI in drug discovery techniques offer new possibilities to generate higher-quality drug candidates in less time and at lower costs.
This blog post provides an overview of core AI methods being applied in drug discovery and examples of leading companies pioneering these technologies. We discuss demonstrated benefits and current limitations, along with projections for the future impact of AI on the pharmaceutical sector. While still in its early stages, AI is poised to reshape biopharmaceutical R&D over the coming decade fundamentally.
Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model.
